The trial will examine the efficacy, safety, and pharmacodynamics of S-606001 SRT used with ERT in confirmed LOPD adults.
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results